NEUP
NASDAQNeuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc. (NEUP) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 1 wire item for NEUP, including 1 SEC filing. The most recent was published Oct 23, 2026.
Financial highlights
Full financials- Revenue, FY2026
- $1.17M
- Revenue growth
- -92.5%
- Net income, FY2026
- -$13.45M
- Net margin
- -1145.7%
- Cash
- $19.87M
For fiscal 2026 (ended Jun 30, 2026), from SEC filings. Not investment advice.
News · 26 weeks11-75%
2026-05-102026-11-01
Mix590d
- SEC Filings5(100%)
Latest news
25 items- SECSEC Form 8-K filed by Neuphoria Therapeutics Inc.8-K - Neuphoria Therapeutics Inc. (0001191070) (Filer)
- SECSEC Form DEFA14A filed by Neuphoria Therapeutics Inc.DEFA14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)
- SECSEC Form DEFA14A filed by Neuphoria Therapeutics Inc.DEFA14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)
- SECSEC Form DEF 14A filed by Neuphoria Therapeutics Inc.DEF 14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)
- SECSEC Form 10-K filed by Neuphoria Therapeutics Inc.10-K - Neuphoria Therapeutics Inc. (0001191070) (Filer)
- SECSEC Form DEFA14A filed by Neuphoria Therapeutics Inc.DEFA14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)
- SECNeuphoria Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Changes in Control of Registrant, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Neuphoria Therapeutics Inc. (0001191070) (Filer)
- PRScancell and Neuphoria Therapeutics Announce Merger Agreement and FinancingAll-share transaction creating a combined company to operate as Scancell advancing a pipeline of targeted, off-the-shelf, active immunotherapiesCombined company to be listed on Nasdaq, in addition to Scancell’s existing AIM listingAgreed pro forma merger ownership split: existing Scancell shareholders to own 85.5 per cent. of the combined company, with Neuphoria existing shareholders owning 14.5 per cent.1Financing to fund the global registrational Phase 3 trial for lead programme, iSCIB1+ active immunotherapy in advanced melanoma OXFORD, United Kingdom and BURLINGTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP) ("Scancell") and Neuphoria Therapeutics Inc. (
- PRNeuphoria Responds to the announcement made by London-listed Scancell Holdings plcNeuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to an announcement made by London-listed biotechnology company Scancell Holdings plc ("Scancell"). The Neuphoria Board notes the announcement made by Scancell earlier today about a possible combination with Neuphoria. The Scancell announcement was made follo
- SECNeuphoria Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Neuphoria Therapeutics Inc. (0001191070) (Filer)
- SECSEC Form 10-Q filed by Neuphoria Therapeutics Inc.10-Q - Neuphoria Therapeutics Inc. (0001191070) (Filer)
- SECSEC Form 10-Q filed by Neuphoria Therapeutics Inc.10-Q - Neuphoria Therapeutics Inc. (0001191070) (Filer)
- INSIDERSEC Form 4 filed by Director Wilson David Ian4 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)
- INSIDERSEC Form 4 filed by Director Davies Peter Miles Winston4 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)
- INSIDERSEC Form 4 filed by Director Fisher Alan4 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)
- INSIDERSEC Form 4 filed by Director Ryan Jane4 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Neuphoria Therapeutics Inc.SCHEDULE 13D/A - Neuphoria Therapeutics Inc. (0001191070) (Subject)
- SECNeuphoria Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Neuphoria Therapeutics Inc. (0001191070) (Filer)
- SECNeuphoria Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Neuphoria Therapeutics Inc. (0001191070) (Filer)
- SECSEC Form DEFA14A filed by Neuphoria Therapeutics Inc.DEFA14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)
- PRLeading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director NomineesCompany Urges Shareholders to Follow ISS' Recommendation and Vote the WHITE Proxy Card BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today announced that Institutional Shareholders Services ("ISS"), a leading independent proxy advisory firm, has issued a report recommending that Neuphoria shareholders vote on the WHITE proxy card FOR BOTH of the Company's director nominees – Peter Miles Davies and David Wilson. As previously disclosed, Lynx1 Capital
- SECSEC Form DEFA14A filed by Neuphoria Therapeutics Inc.DEFA14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)
- PRNeuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and PremiumNeuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote "FOR" BOTH of Neuphoria's Nominees on the WHITE Proxy Card BURLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to dissident stockholder, Lynx1 Master Fund LP's ("Lynx1"), revised indication of interest to acquire the Company. Lynx1 Operating Outside Neuphoria's R
- SECSEC Form DEFA14A filed by Neuphoria Therapeutics Inc.DEFA14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)
- PRNeuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 FictionsBURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statements to address what Neuphoria strongly believes is a campaign from Lynx1 Master Fund LP ("Lynx1") full of deception and distraction to deflect attention from its own limitations and its handpicked nominees' shortcomings. The Company urges stockholders to trust Neuphoria's commitment to transparency and value creation over what it believes are Lynx1's fabrications and misdire
NEUP FAQ
9 questionsWhat is the latest news on NEUP?
In the last 30 days Quantisnow tracked 1 wire item for NEUP: 1 SEC filing. The most recent was published on October 23, 2026.What is NEUP revenue?
Neuphoria Therapeutics Inc. (NEUP) reported $1.17M of revenue for fiscal 2026 (ended Jun 30, 2026). That is down 92.5% from the year before.Is NEUP profitable?
No. Neuphoria Therapeutics Inc. reported a net loss of $13.45M for fiscal 2026 (ended Jun 30, 2026).How much cash and debt does NEUP have?
Neuphoria Therapeutics Inc. reported $19.87M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does NEUP stock trade?
Neuphoria Therapeutics Inc. (NEUP) is listed on NASDAQ.What sector and industry is NEUP in?
Neuphoria Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Neuphoria Therapeutics Inc. go public?
Neuphoria Therapeutics Inc. (NEUP) completed its IPO in 2021.What companies are similar to NEUP?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare NEUP side-by-side with any of them on Quantisnow.How can I track NEUP on Quantisnow?
Quantisnow aggregates Neuphoria Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NEUP to receive live email and push alerts on every new disclosure.